-A series of substituted 2-phenacyl-3-phenyl-1H-pyrrole-4-carboxylates were prepared from substituted acetophenones in 6 steps. The final condensations between a chloroenal and an aminoketone were carried out under neutral conditions in parallel to yield the series listed below. Selected pyrrole derivatives proved to be potent hypolipidemic agents lowering serum triglyceride concentrations in CF-1 male mice after 14 days of I.P. administration. One agent orally lowered serum cholesterol in Sprague-Dawley male rats at 2mg/kg/day after 14 days. The agents demonstrated a lowering of mouse serum LDLcholesterol levels and selected compounds showed an elevation of serum HDL-cholesterol levels. The cholesterol concentrations in the liver were raised while the cholesterol and triglyceride contents of the aorta were significantly lowered by the selected trisubstituted pyrrole.
The substituted ethyl-2-phenacyl-3-phenylpyrrole-4-carboxylates were synthesized by a condensation of a beta-chloroenal and an alpha-aminoketone under neutral conditions. They proved to be potent cytotoxic agents against the growth of murine L1210 and P388 leukemias and human HL-60 promyelocytic leukemia, HuT-78 lymphoma, and HeLa-S(3) uterine carcinoma. Selective compounds were active against the growth of Tmolt(3) and Tmolt(4) leukemias and THP-1 acute monocytic leukemia, liver Hepe-2, ovary 1-A9, ileum HCT-8 adenocarcinoma, and osteosarcoma HSO. A mode of action study in HL-60 cells demonstrated that DNA and protein syntheses were inhibited after 60 min at 100 microM. DNA and RNA polymerases, PRPP-amido transferase, dihydrofolate reductase, thymidylate synthase, and TMP kinase activities were interfered with by the agent with reduction of d[NTP] pools. Nonspecific interaction with the bases of DNA and cross-linking of the DNA may play a role in the mode of action of these carboxylates.
N
6
-Benzoyladenine-cyanoborane (2), and 6-triphenylphosphonylpurine-cyanoborane (3) were selected for
investigation of cytotoxicity in murine and human tumor cell lines, effects on human HL-60 leukemic
metabolism and DNA strand scission to determine the feasibility of these compounds as clinical
antineoplastic agents. Compounds 2 and 3 both showed effective cytotoxicity based on ED50 values less than
4 μg/ml for L1210, P388, HL-60, Tmolt3, HUT-78, HeLa-S3 uterine, ileum HCT-8, and liver Hepe-2.
Compound 2 had activity against ovary 1-A9, while compound 3 was only active against prostate PL and
glioma UM. Neither compound was active against the growth of lung 549, breast MCF-7, osteosarcoma
HSO, melanoma SK2, KB nasopharynx, and THP-1 acute monocytic leukemia. In mode of action studies in
human leukemia HL-60 cells, both compounds demonstrated inhibition of DNA and protein syntheses after
60 min at 100 μM. These compounds inhibited RNA synthesis to a lesser extent. The utilization of the DNA
template was suppressed by the compounds as determined by inhibition of the activities of DNA polymerase
α, m-RNA polymerase, r-RNA polymerase and t-RNA polymerase, which would cause adequate inhibition
of the synthesis of both DNA and RNA. Both compounds markedly inhibited dihydrofolate reductase
activity, especially in compound 2. The compounds appeared to have caused cross-linking of the DNA
strands after 24 hr at 100 μM in HL-60 cells, which was consistent with the observed increased in ct-DNA
viscosity after 24 hr at 100 μM. The compounds had no inhibitory effects on DNA topoisomerase I and II
activities or DNA-protein linked breaks. Neither compound interacted with the DNA molecule itself through
alkylation of the nucleotide bases nor caused DNA interculation between base pairs. Overall, these antineoplastic
agents caused reduction of DNA and protein replication, which would lead to killing of cancer
cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.